<DOC>
	<DOCNO>NCT00321464</DOCNO>
	<brief_summary>The purpose study determine denosumab non-inferior zoledronic acid treatment bone metastases subject advance breast cancer .</brief_summary>
	<brief_title>A Study Comparing Denosumab vs. Zoledronic Acid Treatment Bone Metastases Breast Cancer Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Adults histologically cytologically confirm breast adenocarcinoma radiographic evidence least one bone mets Easter Cooperative Oncology Group status 0 , 1 2 ; adequate organ function Current prior IV bisphosphonate administration current prior oral bisphosphonates bone mets life expectancy le 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Fractures</keyword>
	<keyword>Compressions</keyword>
	<keyword>Bisphosphonates</keyword>
	<keyword>Bone metastasis</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Skeletal</keyword>
	<keyword>Radiation</keyword>
	<keyword>Surgery Bone</keyword>
</DOC>